Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ESRRG | P62508 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113247 | 0.92 | CTSS (0.67) | CTSSMAPTLMNAESRRG | |
| SCHEMBL2114507 | 0.90 | CTSS (0.63) | CTSSESRRG | |
| SCHEMBL2112569 | 0.88 | CTSS (0.66) | CTSSMAPTLMNAALDH1A1 | |
| SCHEMBL2112139 | 0.86 | CTSS (0.61) | CTSSMAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2113182 | 0.86 | CTSS (0.65) | CTSSCHRM1CHRM2CHRM4MAPT | |
| SCHEMBL2115286 | 0.82 | CTSS (0.61) | CTSSCHRM1CHRM2CHRM4MAPT | |
| SCHEMBL2115289 | 0.82 | CTSS (0.61) | CTSSCHRM1CHRM2CHRM4MAPT | |
| SCHEMBL2114397 | 0.80 | CTSS (0.73) | CTSSCHRM1CHRM2CHRM4MAPT | |
| SCHEMBL2610222 | 0.80 | CTSS (0.85) | CTSSCHRM1CHRM2CHRM4MAPT | |
| SCHEMBL2726067 | 0.79 | CTSS (0.69) | CTSSCHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | CTSS, CTSZ, CTSV | CTSS 1/4885CHRM1 4241/4885CHRM2 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.